Investor Relations

Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization

Asieris Releases 2022 Annual Report: Make Steady Progress in its Clinical Development, Global Expansion to Treat Genitourinary Tumors, and Implementing its Commercialization Strategy to Provide Integrated Diagnosis-to-Treatment Solutions

Asieris Pharmaceuticals 2022 Q3 Quarterly Report

Highlights of Asieris 2022 Semi-Annual Report

Asieris Pharmaceuticals 2022 Q1 Quarterly Report